Replies to post #135175 on Biotech Values

[poorgradstudent]

Cldx:

You note that rindo is effectively a mutated peptide, and therefore not a strict case of vaccinating with a self-antigen. In effect, this peptide then presents a foreign epitope that therefore has a chance of eliciting an immune response.

I won't necessarily disagree with that, but will add that blp25 is also proposed to present a typically unseen epitope rather than a plain vanilla self-antigen. If I recall correctly, the change in glycosylation of muc1 was supposed to alter the structure in this region so as to expose an area that would normally not be available for recognition. In effect, blp25 is meant to be this foreign epitope. That might mean the onty trials will provide a meaningful readout for cldx's strategy.